

For Immediate Release



## The United Laboratories International Holdings Limited

### TUL's Capsule Casings in Full Compliance with National Safety Standards

(18 April 2012 – Hong Kong) – In view of the recent concern over capsule casings produced by domestic pharmaceutical manufacturers, The United Laboratories International Holdings Limited (“TUL” or the “Group”; Stock code: 3933), one of the leading manufacturers of antibiotics in the PRC would like to emphasize that all capsule casings made by TUL are in full compliance with national safety standards

Safety of drugs is always the first priority of TUL. In addition to having a comprehensive quality assurance system, TUL enforces strict standards in sourcing of raw materials, production, and pre-delivery testing of products. TUL's quality assurance measures are as follows:

- 1. Assurance in Raw Materials.** The Group only uses medical-grade bone gelatin for manufacturing of capsule casings, and never purchases any “blue leather gelatin”. Gelatin suppliers of the Group have obtained “Pharmaceutical Production License” and “Drug Registration Approval” and TUL also conducts supplier audits on a regular basis.
- 2. Quality Assurance System.** The Group has passed ISO9001 certification in 2001, and has been operating in strict accordance with the requirements of the quality system to ensure product quality. The Group also conducts a corporate review at least once a year.
- 3. Assurance on Production Process.** The Group's production facilities are equipped with clean rooms for microbial limit tests in compliance with the 2010 revised GMP Standard. TUL regularly monitors and ensures the production process follow strict industry standards.
- 4. Assurance on Production Process.** The Group conducts comprehensive inspections on physical and chemical properties (including testing of chromium), defects, microbial limit tests and pathogen screening of capsule casings upon completion of each production batch. The same batch of capsule casings will need to pass evaluation of production condition before delivery.

### **Company Information**

Listed on the Stock Exchange of Hong Kong in June 2007, TUL is one of the leading pharmaceutical companies in China, principally engaged in the manufacturing and selling of medicines, and the bulk and intermediate products used to produce finished goods. As of 31 December 2011, the Group has a total of 184 products qualified to produce in the PRC and/or Hong Kong based on the Drug Registration Approvals in the PRC and Certificates of Drug or Product Registration in Hong Kong. 84 were in production, and 34 were listed in Insurance Catalogue. 12 finished products are in the list of the Nation's Essential Drugs List.

**For further enquiries, please contact:  
iPR Ogilvy Ltd.**

Callis Lau / Tina Law / Jenny Yung / Kiki Zhang / Wallace Tam

Tel: (852) 2136 6952 / 2136 6181 / 3920 7634 / 3920 7626 / 3920 7640

Fax: (852) 3170 6606

email: [callis.lau@iprogilvy.com](mailto:callis.lau@iprogilvy.com) / [tina.law@iprogilvy.com](mailto:tina.law@iprogilvy.com) /  
[jenny.yung@iprogilvy.com](mailto:jenny.yung@iprogilvy.com) / [kiki.zhang@iprogilvy.com](mailto:kiki.zhang@iprogilvy.com) /  
[wallacesm.tam@iprogilvy.com](mailto:wallacesm.tam@iprogilvy.com)